Moderna and Recordati collaborate on rare disease mRNA therapy

Credit: testing / Shutterstock.com

Moderna is collaborating with Recordati to develop its mRNA-3927 for propionic acidemia, a rare metabolic disorder with a lack of available disease modifying treatment.

Intravenous administration of mRNA-3927 is designed to restore functional propionyl-CoA carboxylase (PCC) enzymes in patients with propionic acidemia.

Under the collaboration and license agreement, which is potentially worth in excess of $150 million, Moderna will continue advance mRNA-3927, with Recordati leading global commercialisation if the therapy is approved.

Recordati will pay Moderna $50 million upfront and further milestone payments of up to $110 million, if these are reached.

Rob Koremans, Chief Executive Officer at Recordati, said: “We look forward to partnering with Moderna. Their experience in applying innovative mRNA technology, combined with our experience in rare metabolic disorders and strong established commercial infrastructure, positions us well to advance this potential therapy together to serve patients.

“We are encouraged by the clinical data and look forward to the pivotal readout expected by the end of 2026. This deal strengthens our development portfolio and builds on our heritage in the metabolic field.”

Interim data from a phase I/II study evaluating mRNA-3927 suggest early potential clinical benefit.

Stéphane Bancel, Chief Executive Officer of Moderna, said: “We are proud to partner with Recordati in a joint mission to improve the lives of people living with propionic acidemia. Recordati brings deep rare disease commercial expertise and an established global commercial infrastructure in propionic acidemia that will help us accelerate the benefit of mRNA-3927 upon approval.”

This news builds on Moderna’s $500 million collaboration with Nanexa announced last month, a deal intended to advance mRNA drug delivery and medicines.